Human Epidermal Growth Factor Receptor-2 Gene Amplification in Gastric Cancer Using Tissue Microarray Technology

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2012 Jan 19

PMID 22253521

Citations 16

Authors

Dimitrios Tsapralis

Ioannis Panayiotides

George Peros

Theodore Liakakos

Eva Karamitopoulou

Affiliations

Soon will be listed here.

Abstract

Aim: To assess human epidermal growth factor receptor-2 (HER2)-status in gastric cancer and matched lymph node metastases by immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH).

Methods: 120 cases of primary gastric carcinomas and 45 matched lymph node metastases from patients with full clinicopathological features were mounted onto multiple-punch and single-punch tissue microarrays, respectively, and examined for HER2 overexpression and gene amplification by IHC and CISH.

Results: Twenty-four tumors (20%) expressed HER2 immunohistochemically. An IHC score of ≥ 2+ was observed in 20 tumors (16.6%). HER2 amplification was detected by CISH in 19 tumors (15.8%) and in their matched lymph node metastases. A high concordance rate was found between HER2 positivity (as detected by IHC) and HER2 gene amplification (as detected by CISH), since 19 of the 20 IHC positive cases were amplified (95%). All amplified cases had 2+ or 3+ IHC results. Amplification was associated with intestinal phenotype (P < 0.05). No association with grading, staging or survival was found.

Conclusion: In gastric cancer, HER2 amplification is the main mechanism for HER2 protein overexpression and is preserved in lymph node metastases.

Citing Articles

A Standardized Pathology Report for Gastric Cancer: 2nd Edition.

Park Y, Kook M, Kim B, Lee H, Kang D, Gu M J Gastric Cancer. 2023; 23(1):107-145.

PMID: 36750994 PMC: 9911618. DOI: 10.5230/jgc.2023.23.e7.

A standardized pathology report for gastric cancer: 2nd edition.

Park Y, Kook M, Kim B, Lee H, Kang D, Gu M J Pathol Transl Med. 2023; 57(1):1-27.

PMID: 36647283 PMC: 9846007. DOI: 10.4132/jptm.2022.12.23.

Tumor-Infiltrating Neutrophils and Non-Classical Monocytes May Be Potential Therapeutic Targets for HER2 Gastric Cancer.

Jeong J, Kim D, Park J, Park D, Lee H, Yang H Immune Netw. 2021; 21(4):e31.

PMID: 34522444 PMC: 8410991. DOI: 10.4110/in.2021.21.e31.

Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer.

Kotani D, Shitara K Ther Adv Med Oncol. 2021; 13:1758835920986518.

PMID: 33473250 PMC: 7797586. DOI: 10.1177/1758835920986518.

Hedgehog signaling activation required for glypican-6-mediated regulation of invasion, migration, and epithelial-mesenchymal transition of gastric cancer cells.

Zeng C, Yan R, Yang G, Xiang S, Zhao F Biosci Rep. 2020; 40(6).

PMID: 32478377 PMC: 7295629. DOI: 10.1042/BSR20193181.

References

Kim M, Jung E, Lee H, Lee H, Jeon Y, Yang H . Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol. 2007; 38(9):1386-93. DOI: 10.1016/j.humpath.2007.02.005. View

Im S, Lee K, Nam E, Kim D, Lee J, Han H . Potential prognostic significance of p185(HER2) overexpression with loss of PTEN expression in gastric carcinomas. Tumori. 2006; 91(6):513-21. DOI: 10.1177/030089160509100612. View

Kollmannsberger C, Pressler H, Mayer F, Kanz L, Bokemeyer C . Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab. Ann Oncol. 2000; 10(11):1393-4. DOI: 10.1023/a:1008365216323. View

Prat A, Parera M, Reyes V, Peralta S, Cedres S, Andreu J . Successful treatment of pulmonary metastatic salivary ductal carcinoma with trastuzumab-based therapy. Head Neck. 2007; 30(5):680-3. DOI: 10.1002/hed.20714. View

Francis G, Jones M, Beadle G, Stein S . Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagn Mol Pathol. 2009; 18(2):88-95. DOI: 10.1097/PDM.0b013e31816f6374. View

Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y . Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer. 2002; 98(6):833-7. DOI: 10.1002/ijc.10257. View

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Leyland-Jones B . Trastuzumab therapy for the metastatic patient: does the primary match?. Ann Oncol. 2002; 13(7):993-4. DOI: 10.1093/annonc/mdf295. View

Kanta S, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A . Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum Pathol. 2006; 37(10):1333-43. DOI: 10.1016/j.humpath.2006.05.008. View

10.

Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W . Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008; 52(7):797-805. DOI: 10.1111/j.1365-2559.2008.03028.x. View

11.

Goethals L, Perneel C, Debucquoy A, De Schutter H, Borghys D, Ectors N . A new approach to the validation of tissue microarrays. J Pathol. 2006; 208(5):607-14. DOI: 10.1002/path.1934. View

12.

Bartlett J, Going J, Mallon E, Watters A, Reeves J, Stanton P . Evaluating HER2 amplification and overexpression in breast cancer. J Pathol. 2001; 195(4):422-8. DOI: 10.1002/path.971. View

13.

Garcia I, Vizoso F, Martin A, Sanz L, Abdel-Lah O, Raigoso P . Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol. 2003; 10(3):234-41. DOI: 10.1245/aso.2003.05.010. View

14.

Zhang D, Salto-Tellez M, Do E, Putti T, Koay E . Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol. 2003; 34(4):362-8. DOI: 10.1053/hupa.2003.60. View

15.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

16.

Tripathy D, Slamon D, Cobleigh M, Arnold A, Saleh M, Mortimer J . Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004; 22(6):1063-70. DOI: 10.1200/JCO.2004.06.557. View

17.

Park K, Kim J, Lim S, Han S, Lee J . Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Mod Pathol. 2003; 16(9):937-43. DOI: 10.1097/01.MP.0000086487.78558.7D. View

18.

Yano T, Doi T, Ohtsu A, Boku N, Hashizume K, Nakanishi M . Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 2005; 15(1):65-71. View

19.

Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F . HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol. 2007; 19(1):56-62. DOI: 10.1097/GCO.0b013e328012980a. View

20.

Hynes N, Lane H . ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5(5):341-54. DOI: 10.1038/nrc1609. View